Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lexaria Bioscience (LEXX) Equity Average (2016 - 2025)

Lexaria Bioscience's Equity Average history spans 10 years, with the latest figure at $3.8 million for Q4 2025.

  • For Q4 2025, Equity Average fell 55.94% year-over-year to $3.8 million; the TTM value through Nov 2025 reached $3.8 million, down 55.94%, while the annual FY2025 figure was $5.3 million, 2.99% up from the prior year.
  • Equity Average for Q4 2025 was $3.8 million at Lexaria Bioscience, down from $4.3 million in the prior quarter.
  • Across five years, Equity Average topped out at $12.3 million in Q4 2021 and bottomed at $3.0 million in Q4 2023.
  • The 5-year median for Equity Average is $7.4 million (2022), against an average of $7.4 million.
  • The largest annual shift saw Equity Average skyrocketed 470.08% in 2021 before it plummeted 55.94% in 2025.
  • A 5-year view of Equity Average shows it stood at $12.3 million in 2021, then tumbled by 44.71% to $6.8 million in 2022, then tumbled by 55.38% to $3.0 million in 2023, then surged by 181.74% to $8.5 million in 2024, then tumbled by 55.94% to $3.8 million in 2025.
  • Per Business Quant, the three most recent readings for LEXX's Equity Average are $3.8 million (Q4 2025), $4.3 million (Q3 2025), and $6.2 million (Q2 2025).